Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
79,376,583
-
Total 13F shares
-
30,844,129
-
Share change
-
+1,823,934
-
Total reported value
-
$813,955,792
-
Price per share
-
$25.80
-
Number of holders
-
94
-
Value change
-
+$45,233,337
-
Number of buys
-
45
-
Number of sells
-
38
Institutional Holders of Akero Therapeutics, Inc. - COMMON STOCK (AKRO) as of Q4 2020
As of 31 Dec 2020,
Akero Therapeutics, Inc. - COMMON STOCK (AKRO) was held by
94 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,844,129 shares.
The largest 10 holders included
ATP Life Science Ventures, L.P., JANUS HENDERSON GROUP PLC, venBio Partners LLC, Redmile Group, LLC, ALKEON CAPITAL MANAGEMENT LLC, WELLINGTON MANAGEMENT GROUP LLP, HILLHOUSE CAPITAL ADVISORS, LTD., BlackRock Inc., VANGUARD GROUP INC, and BOXER CAPITAL, LLC.
This page lists
94
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.